medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-17-15-18medalphabet-2745Research ArticleСтатьиВарианты течения хронической сердечной недостаточности у больных с сердечно-сосудистой патологией после перенесенной коронавирусной инфекцииVariants of course of chronic heart failure in patients with cardiovascular pathology after coronavirus infectionhttps://orcid.org/0000-0003-0250-0052ПанинаЮ. Н.PaninaYu. N.

Юлия Николаевна Панина, к. м. н., доцент

кафедра внутренних болезней

Орел

Iuliia N. Panina, PhD Med, associate professor

Dept of Internal Diseases

Orel

doc.panina@yandex.ruhttps://orcid.org/0000-0001-5406-7065ВишневскийВ. И.VishnevskiiV. I.

Валерий Иванович Вишневский, д. м. н., проф., зав. кафедрой

кафедра внутренних болезней

Орел

Valerii I. Vishnevskii, professor, holder of advanced doctorate in medical sciences, head of Dept

Dept of Internal Diseases

Orel

Медицинский институт ФГБОУ ВО «Орловский государственный университет имени И. С. Тургенева»РоссияOrel State University n. a. I. S. TurgenevRussian Federation202207092022017Кардиология. Неотложная медицина (2)1518Copyright © Панина Ю.Н., Вишневский В.И., 20222022Панина Ю.Н., Вишневский В.И.Panina Y.N., Vishnevskii V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2745

   В статье проанализированы значимые для клиницистов исследования, направленные на понимание этиопатогенетических механизмов, которые способствуют развитию ишемической, неишемической и вызванной вирусами или бактериями сердечной недостаточности. Проведен систематический поиск литературы за 2019–2021 годы в PubMed, EuropePMC, SCOPUS, Кокрановской центральной базе данных и medRxiv, использованы поисковые запросы «сердечная недостаточность» и COVID-19, затем мы сконцентрировались на публикациях, которые содержат данные о вариантах течения хронической сердечной недостаточности у больных с сердечно-сосудистой патологией после перенесенной коронавирусной инфекции и провели их анализ с последующим теоретическим моделированием. Распространенность хронической сердечной недостаточности среди населения, восприимчивого к COVID-19, значительна, равно как и распространенность предрасполагающих состояний, которые подвергают инфицированных пациентов риску развития сердечной недостаточности во время болезни и в отдаленном периоде после выздоровления. По этой причине распространение глубоких знаний о клинических последствиях и прогностическом влиянии COVID-19 на эту уязвимую категорию является приоритетом.

   This article analyzes studies that are significant for clinicians aimed at understanding the etiopathogenetic mechanisms that contribute to the development of ischemic, non-ischemic and viral/bacterial-induced heart failure. A systematic search of literature for 2019–2021 was conducted in PubMed, EuropePMC, SCOPUS, the Cochrane Central Database and medRxiv using the search queries ‘Heart Failure’ and ‘COVID-19’; then we focused on publications that contain data on variants of the course of chronic heart failure in patients with cardiovascular pathology after a coronavirus infection and analyzed them with subsequent theoretical modeling. The prevalence of chronic heart failure among the population susceptible to COVID-19 is significant, as is the prevalence of predisposing conditions that expose infected patients to the risk of developing heart failure during illness and in the long-term period after recovery. For this reason, the dissemination of in-depth knowledge about the clinical consequences and prognostic impact of COVID-19 on this vulnerable category is a priority.

хроническая сердечная недостаточностьCOVID-19ремоделирование сердцабиомаркерыфиброз миокардаотсроченные послеинфекционные осложненияchronic heart failureCOVID-19cardiac remodelingbiomarkersmyocardial fibrosisdelayed postinfectious complicationsReferencesAlon D. et al. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PloS one 2013; 8: e72476.Alon D. et al. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PloS one 2013; 8: e72476.Mehra M. R., Ruschitzka F. COVID-19 illness and heart failure: a missing link? JACC Heart Fail 2020; 8: 512–4.Mehra M. R., Ruschitzka F. COVID-19 illness and heart failure: a missing link? JACC Heart Fail 2020; 8: 512–4.Zheng Y. Y., Ma Y. T., Zhang J..Y et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17: 259–60.Zheng Y. Y., Ma Y. T., Zhang J..Y et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17: 259–60.Fung G. et al. Myocarditis. Circulation research 2016; 118: 496–514.Fung G. et al. Myocarditis. Circulation research 2016; 118: 496–514.Sikder S. et al. Group G streptococcus induces an autoimmune carditis mediated by interleukin 17A and interferon γ in the Lewis rat model of rheumatic heart disease. The Journal of infectious diseases 2018; 218: 324–335.Sikder S. et al. Group G streptococcus induces an autoimmune carditis mediated by interleukin 17A and interferon γ in the Lewis rat model of rheumatic heart disease. The Journal of infectious diseases 2018; 218: 324–335.Puntmann V. O. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA cardiology 2020; 5: 1265–1273.Puntmann V. O. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA cardiology 2020; 5: 1265–1273.Maier C. L. et al. COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? The Lancet 2020; 395: 1758–1759.Maier C. L. et al. COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? The Lancet 2020; 395: 1758–1759.Yonas E. et al. Effect of heart failure on the outcome of COVID-19 – a meta-analysis and systematic review. The American journal of emergency medicine 2021; 46: 204–211.Yonas E. et al. Effect of heart failure on the outcome of COVID-19 – a meta-analysis and systematic review. The American journal of emergency medicine 2021; 46: 204–211.Weirather J. et al. Foxp3+ CD 4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circulation research 2014; 115: 55–67.Weirather J. et al. Foxp3+ CD 4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circulation research 2014; 115: 55–67.Bansal S. S. et al. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circulation: Heart Failure 2017; 10: e003688.Bansal S. S. et al. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circulation: Heart Failure 2017; 10: e003688.Bromage D. I. et al. The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. European journal of heart failure 2020; 22: 978–984.Bromage D. I. et al. The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. European journal of heart failure 2020; 22: 978–984.Messerli F. H., Rimoldi S. F., Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC: Heart Failure 2017; 8: 543–551.Messerli F. H., Rimoldi S. F., Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC: Heart Failure 2017; 8: 543–551.Patel B. et al. CCR 2+ monocyte-derived infiltrating macrophages are required for adverse cardiac remodeling during pressure overload, JACC: Basic to Translational Science 2018; 2: 230–244.Patel B. et al. CCR 2+ monocyte-derived infiltrating macrophages are required for adverse cardiac remodeling during pressure overload, JACC: Basic to Translational Science 2018; 2: 230–244.Kallikourdis M. et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nature communications 2017; 8: 1–14.Kallikourdis M. et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nature communications 2017; 8: 1–14.Yao X. H. et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chinese journal of pathology 2020; 49R: E 009–E 009.Yao X. H. et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chinese journal of pathology 2020; 49R: E 009–E 009.Inciardi R. M. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA cardiology 2020; 7: 819–824.Inciardi R. M. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA cardiology 2020; 7: 819–824.Bradley B. T. et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. The Lancet 2020; 10247: 320–332.Bradley B. T. et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. The Lancet 2020; 10247: 320–332.Li X., Ma X. Acute respiratory failure in COVID-19: is it typical ARDS? Critical Care 2020; 1: 1–5.Li X., Ma X. Acute respiratory failure in COVID-19: is it typical ARDS? Critical Care 2020; 1: 1–5.Zheng Y. Y., Ma Y. T., Zhang J. Y., et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17: 259–260.Zheng Y. Y., Ma Y. T., Zhang J. Y., et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17: 259–260.Luecke T., Pelosi P. Clinical review: positive end-expiratory pressure and cardiac output, crit. Care 2005; 9: 607–621.Luecke T., Pelosi P. Clinical review: positive end-expiratory pressure and cardiac output, crit. Care 2005; 9: 607–621.Puntmann V. O. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA cardiology 2020; 11: 1265–1273.Puntmann V. O. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA cardiology 2020; 11: 1265–1273.

The authors declare that there are no conflicts of interest present.